Nov 10, 2016 13:31 pm UTC| Business
PHILADELPHIA, Nov. 10, 2016 -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 third quarter financial results for the quarter ended...
MetaBank® to acquire the assets of Specialty Consumer Services LP
Nov 10, 2016 13:31 pm UTC| Business
SIOUX FALLS, S.D., Nov. 10, 2016 -- Meta Financial Group, Inc.® (NASDAQ:CASH) (“Meta” or the “Company”) and its bank subsidiary, MetaBank®, have signed a definitive agreement with privately-held Specialty Consumer...
Nov 10, 2016 13:30 pm UTC| Business
CARLSBAD, Calif., Nov. 10, 2016 -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced...
Alternative Data Spend in U.S. to Double in Next Five Years, Says TABB Group Research
Nov 10, 2016 13:30 pm UTC| Business
NEW YORK and LONDON, Nov. 10, 2016 -- The amount of unstructured, alternative data is increasing at a rapid pace, with technology and analysis capabilities also advancing to solve the data’s main constraint of deriving...
Sientra to Present at Investor Conferences in November 2016
Nov 10, 2016 13:30 pm UTC| Business
SANTA BARBARA, Calif., Nov. 10, 2016 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, announced today that Jeff Nugent, President and Chief Executive Officer, and Patrick F. Williams, Chief Financial...
Nov 10, 2016 13:30 pm UTC| Business
Third Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care Top Line Translational Data from...
Fluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels for Immuno-Oncology Research
Nov 10, 2016 13:30 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of a modular set of high-parameter Maxpar® mass cytometry panels for immuno-oncology research. Designed...